
|Articles|March 9, 2011
- December 2010
- Volume 4
- Issue 12
People in Britain Say Find Aliens, Cure Cancer
Author(s)OBTN
A recent poll conducted by Britain's Royal Society found that what Britons want most is a vaccine that will prevent cancer.
Advertisement
A recent poll conducted by Britain’s Royal Society found that what Britons want most is a vaccine that will prevent cancer, with nearly 80% of respondents selecting it as their top priority for science. Of the 2000 people surveyed, 60% picked HIV/AIDS prevention as their next choice. Although 44% expressed a belief in aliens and more than one-third think scientists should be trying to find and contact them, less than 10% identified space exploration as a top priority for science.
Articles in this issue
over 15 years ago
Medulloblastoma Subtypes Are Different Diseasesover 15 years ago
ASH 2010: Elotuzumab Highly Active in Patients With Advanced Myelomaover 15 years ago
FDA Requests Label Change for Generic DocetaxelAdvertisement
Related to this article

PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.

A phase 2 study of neoadjuvant cemiplimab in HHI-naive BCC of the head and neck produced a 60.1% ORR and a 42.9% surgical benefit rate.

The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.

Nirav N. Shah, MD, MSHP, and Alexey Danilov, MD, PhD, discuss the phase 2 DAYBreak CLL-201 trial evaluating bexobrutideg in relapsed/refractory CLL.

Nirav N. Shah, MD, MSHP, discusses bexobrutideg and what the BTK degrader could bring to chronic lymphocytic leukemia management.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
3
Longer-Term Data Help Shape TKI Selection in ROS1+ and ALK+ NSCLC
4
Experts Revisit the Most Notable Data in GU Oncology From ASCO 2026
5



